Skip to main content

Table 6 Clinical and neuropathological criteria

From: A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer’s disease

Study

Sample

Database

Neuropathological criteria

Autopsy

Dementia criteria

McKeith et al ., 1992 [[20]]

AD 37

Newcastle, UK

AD: plaque/tangle quantification, H + E, CFV, Loyez, Palmgren.

All

DLB: proposed consensus (1992)

SDLT 21

LB: H + E, pholxine, erythrosin

Ballard et al ., 1996 [[17]]

AD 53

West Midlands and Bristol, UK

 

0

AD: NINCDS/ADRDA (1984)

SDLT 7

DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992)

VaD 14

Ballard et al., 1998 [[21]]

AD 30

Newcastle General Hospital, UK

AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren

19

AD: NINCDS/ADRDA (1984)

DLB 42

DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992)

LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB

Olichney et a l., 1998 [[3]]

AD 148

Cohort from:

AD: CERAD, ADRC

All

AD: NINCDS/ADRDA (1984),

LBV 40

Univeristy of California, San Diego Alzheimer’s Disease Research Center, USA;

LB: ubiquitin, H + E (brainstem, cerebral cortex)

DSM-III for dementia

CERAD centers, multinational

Heyman et al ., 1999 [[18]]

AD 74

Subjects with premortem diagnosis of probable and possible AD from 24 centers participating in CERAD, 1986 to 1995, USA

AD: CERAD

All

AD: NINCDS/ADRDA (1984)

AD/LBV 27

LB: consensus criteria (1996), modified (brainstem, limbic/transitional and noecortical).

Lopez et al ., 2000 [[22]]

AD 98

University of Pittsburg 1983 to 1998, USA

AD: CERAD, NIA-RI

All

AD: NINCDS/ADRDA (1984)

AD/DLB 44

LB: H + E, ubiqutin (SN, neocortex, limbic areas)

DLB: consensus criteria (1996)

Stern et al . 2001 [[23]]

AD 32

From cohort of 236 patients with probable AD

AD: CERAD

All

AD: NINCDS/ADRDA (1984)

LBV 19

LB: semi quantitative ubiquitin (SN, hippocampus, cingulate gyrus, insula cortex)

Recruited:

Columbia University College, New York, USA

Johns Hopkins University, Baltimore, USA

Massachusetts General Hospital, Boston, USA

Ballard et al ., 2001 [[24]]

AD 101

Cohort of 227 patients

AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren

50

AD: NINCDS/ADRDA (1984)

DLB 64

Institute of the Health of the Elderly (IHE), Newcastle, UK

DLB: consensus criteria (1996)

VaD 38

LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB

Helmes et al ., 2003 [[25]]

AD 15

University of Western Ontario Dementia Study, Canada

No criteria are referred to. Only referred to LB staining methods (Bielschovsky, anti-ubiquitin, anti-synuclein).

All

Not specified.

AD/DLB 8

DLB 7

Johnson et al ., 2005 [[26]]

AD 66

Washington University, from 1979, USA

AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions

All

AD: NINCDS/ADRDA (1984)

AD/DLB 57

DLB: consensus criteria (1996) or McKeith, operational criteria for senile dementia of Lewy body type (1992)

DLB 9

LB: synuclein

Kraybill et al ., 2005 [[15]]

AD 48

Cohort from University of Washington/Group Health Cooperative Alzheimer’s Disease Patient Registry, USA

AD: CERAD, Braak stages > IV

All

AD: NINCDS/ADRDA (1984)

AD/LBP 65

LB/AD: AD + synuclein (amygdala, SN)

DLB: missing criteria because study was started before the consensus criteria for DLB was established.

LBP 22

LB: Braak stages < III, synuclein (amygdala, SN)

Stavitsky et a l., 2006 [[19]]

AD 55

Cohort of the Predictors Study, 1997:

AD: CERAD

12

AD: NINCDS/ADRDA (1984)

DLB 28

LB: semi quantitative ubiquitin (hippocampus, cingulate gyrus, insula cortex)

DLB: consensus criteria (1996)

Columbia University

Johns Hopkins University,

Massachusetts General Hospital, USA

Williams et al ., 2006 [[27]]

AD 252

Cohort from Washington University, USA

AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions

All

AD: NINCDS/ADRDA (1984)

DLB 63

DLB: consensus criteria (1996)

LB: synuclein

Hamilton et al ., 2008 [[28]]

AD 44

University of California, Alzheimer’s disease center San Diego, 1985 to 2002, USA

AD: modified Braak staging, NIA-RI (1997) and CERAD (1991)

All

AD: NIA-RI and CERAD (1988)

DLB 22

DLB: consensus criteria (1996)

LB: H + E, ubiquitin (1996) synuclein (2005)

Hanyu et al ., 2009 [[29]]

AD 111

Memory Clinic of Tokyo Medical University, 2000 to 2006, Japan

 

0

AD: NINCDS/ADRDA (1984)

DLB 56

DLB: consensus criteria (1996)

Nelson et al ., 2009 [[16]]

AD 107

National Alzheimer’s Coordinating Center (NACC) Registry - 31 AD centers in USA,

AD: NIA-RI

All

AD: CERAD (1988)

AD/DLB 27

University of Kentucky Alzheimer’s Disease Center, USA

LB: Braak staging and CERAD

DLB: consensus criteria (1996)

DLB 9

Wood et a l., 2012 [[30]]

AD 16

Newcastle University, UK

 

0

AD: NINCDS/ADRDA (1984)

DLB 12

DLB: consensus criteria (2005) or (1996)

Walker et al . 2012 [[31]]

AD 100

40 European sites

123I-FTP-SPECT as verifying method

0

AD: NINCDS/ADRDA (1984)

DLB 58

DLB: consensus criteria (1996)

  1. AD, Alzheimer’s disease; ADRC, Alzheimer’s Disease Research Center; CERAD, The Consortium to Establish a Registry for Alzheimer's Disease; CFV, creasyl fast violet; DLB, dementia with Lewy bodies; H + E, hematoxylin and eosin staining; I-FTP-SPECT, ioflupane single-photon emission computed tomography; LB Lewy body; LBV, Lewy body variant; LBP, Lewy body pathology; NIA-RI, National Institute on Aging-Reagan; NINCDS/ADRDA, National Institute of Neurological and Communication Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association; SDLT, senile dementia of Lewy body type; SN, substantia nigra.